Predicting the Response to the Treatment of Hepatitis C Virus Infection

Overview

Journal Clin Liver Dis (Hoboken)

Specialty Gastroenterology

Date 2019 Jun 13

PMID 31186846

Authors

David L Thomas

Affiliations

Soon will be listed here.

References

Hadziyannis S, Sette Jr H, Morgan T, Balan V, Diago M, Marcellin P . Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004; 140(5):346-55. DOI: 10.7326/0003-4819-140-5-200403020-00010. View

Legrand-Abravanel F, Sandres-Saune K, Barange K, Alric L, Moreau J, Desmorat P . Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis. 2004; 189(8):1397-400. DOI: 10.1086/382544. View

Muir A, Bornstein J, Killenberg P . Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004; 350(22):2265-71. DOI: 10.1056/NEJMoa032502. View

Torriani F, Rodriguez-Torres M, Rockstroh J, Lissen E, Gonzalez-Garcia J, Lazzarin A . Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004; 351(5):438-50. DOI: 10.1056/NEJMoa040842. View

Derbala M, Amer A, Bener A, Lopez A, Omar M, El Ghannam M . Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat. 2005; 12(4):380-5. DOI: 10.1111/j.1365-2893.2005.00604.x. View

Shiffman M, Suter F, Bacon B, Nelson D, Harley H, Sola R . Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med. 2007; 357(2):124-34. DOI: 10.1056/NEJMoa066403. View

Rodriguez-Torres M, Jeffers L, Sheikh M, Rossaro L, Ankoma-Sey V, Hamzeh F . Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med. 2009; 360(3):257-67. DOI: 10.1056/NEJMoa0805062. View

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N . Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009; 41(10):1105-9. DOI: 10.1038/ng.449. View

Thomas D, Thio C, Martin M, Qi Y, Ge D, OhUigin C . Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265):798-801. PMC: 3172006. DOI: 10.1038/nature08463. View

10.

Thompson A, Muir A, Sulkowski M, Ge D, Fellay J, Shianna K . Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010; 139(1):120-9.e18. DOI: 10.1053/j.gastro.2010.04.013. View

11.

Mangia A, Thompson A, Santoro R, Piazzolla V, Tillmann H, Patel K . An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. 2010; 139(3):821-7, 827.e1. DOI: 10.1053/j.gastro.2010.05.079. View

12.

Lam K, Trinh H, Do S, Nguyen T, Garcia R, Nguyen T . Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Hepatology. 2010; 52(5):1573-80. DOI: 10.1002/hep.23889. View

13.

Labarga P, Soriano V, Caruz A, Poveda E, Di Lello F, Di Lello F . Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. AIDS. 2011; 25(6):761-6. DOI: 10.1097/QAD.0b013e32834488e7. View

14.

Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. PMC: 3766849. DOI: 10.1056/NEJMoa1010494. View

15.

Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie A, Reddy K, Bzowej N . Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. DOI: 10.1056/NEJMoa1012912. View

16.

Deltenre P, Louvet A, Lemoine M, Mourad A, Fartoux L, Moreno C . Impact of insulin resistance on sustained response in HCV patients treated with pegylated interferon and ribavirin: a meta-analysis. J Hepatol. 2011; 55(6):1187-94. DOI: 10.1016/j.jhep.2011.03.010. View